An observational study in Focal Liver Lesions and Contrast-enhanced Ultrasound, sponsored by Ping Liang. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2020-12-24.
Sponsored by Ping Liang · Observational
Contrast-enhanced ultrasound (CEUS) substantially improves the potential of ultrasound (US) for the identification and characterization of focal liver lesions (FLLs). Compared to contrasted-enhanced MRI and CT, it has some unique advantages, such as the absence of ionizing radiation, and easy operability and repeatability. However, the efficacy of CEUS in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, and low interobserver agreement. Therefore, it is a beneficial attempt to construct an intelligent CEUS diagnosis system using digital information technology. This study aims to collect standard data of CEUS cines recordings and develop deep learning model for accurate segmentation, detection and classification of liver lesions.
Ping Liang is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with focal liver lesions
Exclusion Criteria:
there is no intervention diagnosis or treatment for patients
AUC value
Area under the receiver operating characteristic (ROC) curve (AUC）
Time frame: through study completion, an average of 7 year
specificity
diagnosis specificity of intelligent CEUS analysis
Time frame: through study completion, an average of 7 year
sensitivity
diagnosis sensitivity of intelligent ultrasound analysis
Time frame: through study completion, an average of 3 year
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ping Liang